- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
[作者：McCarthy, PL; Owzar, K; Hofmeister, CC; Hurd, DD; Hassoun, H; Richardson, PG; Giralt, S; Stadtmauer, EA; Weisdorf, DJ; Vij, R; Moreb, JS; Callander, NS; Van Besien, K; Gentile, T; Isola, L; Maziarz, RT; Gabriel, DA; Bashey, A; Landau, H; Martin, T; Qazilbash, MH; Levitan, D; McClune, B; Schlossman, R; Hars, V; Postiglione, J; Jiang, C; Bennett, E; Barry, S; Bressler, L; Kelly, M; Seiler, M; Rosenbaum, C; Hari, P; Pasquini, MC; Horowitz, MM; Shea, TC; Devine, SM; Anderson, KC; Linker, C,期刊：New England Journal of Medicine, 页码：1770-1781 , 文章类型： Article，,卷期：2012年366-19]
- Background Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. Methods Between...
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
[作者：Attal, M; Lauwers-Cances, V; Marit, G; Caillot, D; Moreau, P; Facon, T; Stoppa, AM; Hulin, C; Benboubker, L; Garderet, L; Decaux, O; Leyvraz, S; Vekemans, MC; Voillat, L; Michallet, M; Pegourie, B; Dumontet, C; Roussel, M; Leleu, X; Mathiot, C; Payen, C; Avet-Loiseau, H; Harousseau, JL,期刊：New England Journal of Medicine, 页码：1782-1791 , 文章类型： Article，,卷期：2012年366-19]
- Background High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is respons...
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
[作者：Palumbo, A; Hajek, R; Delforge, M; Kropff, M; Petrucci, MT; Catalano, J; Gisslinger, H; Wiktor-Jedrzejczak, W; Zodelava, M; Weisel, K; Cascavilla, N; Iosava, G; Cavo, M; Kloczko, J; Blade, J; Beksac, M; Spicka, I; Plesner, T; Radke, J; Langer, C; Ben Yehuda, D; Corso, A; Herbein, L; Yu, ZN; Mei, J; Jacques, C; Dimopoulos, MA,期刊：New England Journal of Medicine, 页码：1759-1769 , 文章类型： Article，,卷期：2012年366-19]
- Background Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomi...
- Reproductive Technologies and the Risk of Birth Defects
[作者：Davies, MJ; Moore, VM; Willson, KJ; Van Essen, P; Priest, K; Scott, H; Haan, EA; Chan, A,期刊：New England Journal of Medicine, 页码：1803-1813 , 文章类型： Article，,卷期：2012年366-19]
- Background The extent to which birth defects after infertility treatment may be explained by underlying parental factors is uncertain. Methods We linked a census of treatment with assisted reproductive technology in Sout...
|